AffaMed Technologies secures exclusive rights for revolutionary EVOLUX® IOL in Greater China market

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI, a leading international ophthalmology company headquartered in Italy. Image credit: ©.shock – stock.adobe.com

AffaMed Technologies announced it has entered into an agreement with SIFI under which AffaMed has obtained the exclusive rights to manufacture, develop and commercialise EVOLUX®.

A signing ceremony was held in Beijing, where the CEOs of AffaMed Therapeutics and SIFI celebrated this expansion of AffaMed's portfolio of IOLs for the Greater China market, according to the company in a press release.¹

EVOLUX® is a novel extended monofocal IOL, based on a hydrophobic material and a non-diffractive profile, designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL, according to AffaMed.¹ AffaMed Technologies now has the exclusive rights to develop, manufacture and commercialise the MINI WELL®, MINI WELL TORIC®, MINI WELL PROXA®, EVOLUX® and MINI 4® Ready lines of IOLs in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong, after the agreement with SIFI.

During the signing ceremony, the CEOs of the companies also celebrated successes the companies have made since their partnership started in April 2021.¹ These included:

• Completion of enrollment in the China Registrational Clinical Trial of its MINI WELL® Extended Depth-of-Focus ("EDOF") IOL
• Completion of the first patient implantations of its EDOF IOLs conducted in Boao, China, under the "Early and Pilot Implementation" policy
• TFDA Approval of MINI WELL®, MINI WELL PROXA®, MINI WELL TORIC® and MINI 4® Ready IOLs for cataract treatment in Taiwan
• Successful relaunch of MINI WELL®, MINI WELL PROXA®, MINI WELL TORIC® and MINI 4® Ready IOLs in Hong Kong and Macau under a strategic sales and distribution partnership

"We are excited about the potential of Evolux to address the growing needs of patients in China in this new age" said Dayao Zhao, MD, PhD, CEO of AffaMed Therapeutics. "Visual needs have evolved in the recent decades, many older adults work beyond retirement age and live a more active life than in the past, they spend several hours per day on activities requiring good intermediate vision such as driving, reading price tags when shopping, cooking, reading at PC/tablet distance, or walking on uneven ground conditions. Choosing a monofocal IOL improving intermediate vision means helping patients with their everyday activities and making their life easier. We look forward to advancing Evolux towards regulatory approval, and to be able to bring its significant benefits in vision correction to patients in China in the near future."

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI, a leading international ophthalmology company headquartered in Italy, to develop, manufacture and commercialise premium IOLs in the Greater China market.

References:

1. AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL. Press Release. Released October 10, 2023. Accessed October 11, 2023. https://www.prnewswire.com/news-releases/affamed-technologies-announces-licensing-of-evolux--a-novel-extended-monofocal-intraocular-lens-iol-designed-to-provide-better-intermediate-vision-and-equivalent-distance-vision-when-compared-to-a-standard-monofocal-iol-301950812.html